PDF下载 ( 730 KB)
大黄素防治慢性肝病作用机制的研究现状
DOI: 10.12449/JCH260130
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：陈雅洁负责设计论文框架及撰写文章；王昕负责拟定写作思路、指导撰写文章与终稿审定；武云娟、王钰涵负责绘制机制图；苏莹、张金雪、秦英、左小宁负责论文修改；姚凝负责指导撰写文章。
Current status of research on the mechanism of action of emodin in the prevention and treatment of chronic liver diseases
-
摘要: 慢性肝病是指肝脏因长期受到各种损伤，出现持续时间超过6个月且不可逆性病理改变的疾病。大黄素（EMO）是一种来源于大黄的天然蒽醌衍生物，其药理作用已被广泛研究，表现出多种生物特性并涉及多个信号分子和途径。目前针对慢性肝病的治疗方案以西药或手术治疗为主，由于副作用、高成本等多种原因，治疗推进受限。EMO因其天然来源和疗效，在治疗慢性肝病方面具有独特的优势，现已成为研究热点。本文通过总结梳理EMO对慢性肝病的治疗作用并探讨其机制，以期为慢性肝病的中医药治疗与临床药物研发提供一定的科学依据。Abstract: Chronic liver diseases are a group of diseases in which the liver is subjected to a variety of injuries over a long period of time， resulting in irreversible pathological changes that last longer than 6 months. Emodin （EMO） is a natural anthraquinone derivative derived from Rheum officinale， and its pharmacological effect has been extensively studied， exhibiting a variety of biological properties and involving multiple signaling molecules and pathways. Western medicine or surgical treatment is currently the main treatment regimen for chronic liver diseases， and the advance in treatment is limited by various reasons such as side effects and high costs. Due to its natural origin and efficacy， EMO has unique advantages in the treatment of chronic liver diseases and has now become a research hotspot. This article summarizes the therapeutic effect of EMO on chronic liver diseases and its mechanism， in order to provide a certain scientific basis for the traditional Chinese medicine treatment of chronic liver diseases and the development of drugs in clinical practice.
-
Key words:
- Emodin /
- Liver Diseases /
- Signal Transduction
-
注： IL-1β，白细胞介素-1β；IL-6，白细胞介素-6；TNF-α，肿瘤坏死因子-α；IκBα，核因子κB抑制蛋白α；ASC，凋亡相关斑点样蛋白；Caspase-1，半胱氨酸天冬氨酸酶-1；p38，p38丝裂原活化蛋白激酶；JNK，c-Jun氨基末端激酶；Treg，调节性T细胞；Foxp3，叉头框蛋白P3；ECM，细胞外基质；PDGF，血小板衍生生长因子；TIMP-1，基质金属蛋白酶抑制剂-1；TGF-β，转化生长因子β；EMT，上皮间质转化；MFB，肌成纤维细胞；NF-κB，核因子-κB；NLRP3，NOD样受体热蛋白结构域相关蛋白3；MAPK，丝裂原活化蛋白激酶；AMPK，腺苷酸活化蛋白激酶；SREBP1，固醇调节元件结合蛋白1；PPARα，过氧化物酶体增殖物激活受体α；LKB1，肝脏激酶B1；ATP，三磷酸腺苷；FASN，脂肪酸合成酶；ACC，乙酰辅酶A羧化酶；CPT1A，肉碱脂酰转移酶ⅠA；ACOX1，酰基辅酶A氧化酶1；β-catenin，β-连环蛋白；Cyclin D1，细胞周期蛋白D1。
图 1 EMO分子式及其治疗慢性肝病的作用机制
Figure 1. Diagram of the molecular formula of EMO and its mechanism of action in the treatment of chronic liver disease
-
[1] DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017. [2] FOGLIA B, TURATO C, CANNITO S. Hepatocellular carcinoma: Latest research in pathogenesis, detection and treatment[J]. Int J Mol Sci, 2023, 24( 15): 12224. DOI: 10.3390/ijms241512224. [3] SEMWAL RB, SEMWAL DK, COMBRINCK S, et al. Emodin-A natural anthraquinone derivative with diverse pharmacological activities[J]. Phytochemistry, 2021, 190: 112854. DOI: 10.1016/j.phytochem.2021.112854. [4] LI S, MA Y, CHEN W. Active ingredients of Erhuang Quzhi Granules for treating non-alcoholic fatty liver disease based on the NF-κB/NLRP3 pathway[J]. Fitoterapia, 2023, 171: 105704. DOI: 10.1016/j.fitote.2023.105704. [5] CHEN L, LIANG BY, XIA SW, et al. Emodin promotes hepatic stellate cell senescence and alleviates liver fibrosis via a nuclear receptor(Nur77)-mediated epigenetic regulation of glutaminase 1[J]. Br J Pharmacol, 2023, 180( 19): 2577- 2598. DOI: 10.1111/bph.16156. [6] YU LY, QIN JX, ZHANG M, et al. Research progress on the anti-liver cancer mechanism and toxicity of rhubarb anthraquinone[J]. Drug Des Devel Ther, 2024, 18: 6089- 6113. DOI: 10.2147/DDDT.S489377. [7] LIU MH, ZHANG LH, MA QL, et al. Effects of emodin based on PI3K/AKT/NF-κB signaling pathway in rats with non-alcoholic steatohepatitis[J]. China J Tradit Chin Med Pharm, 2020, 35( 3): 1428- 1432.刘鸣昊, 张丽慧, 马庆亮, 等. 基于PI3K/AKT/NF-κB信号传导通路探讨大黄素对非酒精性脂肪性肝炎模型大鼠的影响[J]. 中华中医药杂志, 2020, 35( 3): 1428- 1432. [8] TU YJ, TAN B, JIANG L, et al. Emodin inhibits lipopolysaccharide-induced inflammation by activating autophagy in RAW 264.7 cells[J]. Chin J Integr Med, 2021, 27( 5): 345- 352. DOI: 10.1007/s11655-020-3477-9. [9] LIU X, WEI W, WU YZ, et al. Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF-κB and its upstream TLR4 signaling[J]. Oncol Lett, 2023, 26( 6): 514. DOI: 10.3892/ol.2023.14101. [10] JIANG N, LI ZX, LUO YL, et al. Emodin ameliorates acute pancreatitis-induced lung injury by suppressing NLRP3 inflammasome-mediated neutrophil recruitment[J]. Exp Ther Med, 2021, 22( 2): 857. DOI: 10.3892/etm.2021.10289. [11] FU W, LIU SC, XU TX, et al. Emodin inhibits NLRP3 inflammasome activation and protects against sepsis via promoting FUNDC1-mediated mitophagy[J]. Int J Biol Sci, 2025, 21( 8): 3631- 3648. DOI: 10.7150/ijbs.110904. [12] LEE JS, KIM HJ, NGUYEN TTH, et al. Emodin 8-O-glucoside primes macrophages more strongly than emodin aglycone via activation of phagocytic activity and TLR-2/MAPK/NF-κB signalling pathway[J]. Int Immunopharmacol, 2020, 88: 106936. DOI: 10.1016/j.intimp.2020.106936. [13] BEI YF, TIA B, LI YZ, et al. Anti-influenza a virus effects and mechanisms of emodin and its analogs via regulating PPARα/γ-AMPK-SIRT1 pathway and fatty acid metabolism[J]. Biomed Res Int, 2021, 2021: 9066938. DOI: 10.1155/2021/9066938. [14] LIU S, LUO XH, LIU YF, et al. Emodin exhibits anti-acne potential by inhibiting cell growth, lipogenesis, and inflammation in human SZ95 sebocytes[J]. Sci Rep, 2023, 13( 1): 21576. DOI: 10.1038/s41598-023-48709-x. [15] WANG SJ, LI XJ, GUO HL, et al. Emodin alleviates hepatic steatosis by inhibiting sterol regulatory element binding protein 1 activity by way of the calcium/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mechanistic target of rapamycin-p70 ribosomal S6 kinase signaling pathway[J]. Hepatol Res, 2017, 47( 7): 683- 701. DOI: 10.1111/hepr.12788. [16] WANG XL, NIU CG, ZHANG XJ, et al. Emodin suppresses activation of hepatic stellate cells through p38 mitogen-activated protein kinase and Smad signaling pathways in vitro[J]. Phytother Res, 2018, 32( 12): 2436- 2446. DOI: 10.1002/ptr.6182. [17] ZHANG BB. Therapeutic effects and mechanisms of emodin on alcoholic liver fibrosis[D]. Luoyang: Henan University of Science and Technology, 2022. DOI: 10.27115/d.cnki.glygc.2022.001056.张兵兵. 大黄素对酒精性肝纤维化的治疗作用及机制研究[D]. 洛阳: 河南科技大学, 2022. DOI: 10.27115/d.cnki.glygc.2022.001056. [18] LIU Q, HODGE J, WANG JF, et al. Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation[J]. Theranostics, 2020, 10( 18): 8365- 8381. DOI: 10.7150/thno.45395. [19] MA WJ, LIU F, YUAN LY, et al. Emodin and AZT synergistically inhibit the proliferation and induce the apoptosis of leukemia K562 cells through the EGR1 and the Wnt/β-catenin pathway[J]. Oncol Rep, 2020, 43( 1): 260- 269. DOI: 10.3892/or.2019.7408. [20] WIBAWA IDN, MARIADI IK, SOMAYANA G, et al. Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management[J]. World J Diabetes, 2023, 14( 5): 549- 559. DOI: 10.4239/wjd.v14.i5.549. [21] HAYAT U, SIDDIQUI AA, FARHAN ML, et al. Genome editing and fatty liver[J]. Adv Exp Med Biol, 2023, 1396: 191- 206. DOI: 10.1007/978-981-19-5642-3_13. [22] ZHANG H, ZHU HW, WU S, et al. Assessment of the purity of IMM-H014 and its related substances for the treatment of metabolic-associated fatty liver disease using quantitative nuclear magnetic resonance spectroscopy[J]. Int J Mol Sci, 2023, 24( 24): 17508. DOI: 10.3390/ijms242417508. [23] NOUREDDIN M, CHARLTON MR, HARRISON SA, et al. Expert panel recommendations: Practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis[J]. Clin Gastroenterol Hepatol, 2024, 22( 12): 2367- 2377. DOI: 10.1016/j.cgh.2024.07.003. [24] SHEN CP, PAN ZS, WU SC, et al. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway[J]. J Ethnopharmacol, 2021, 279: 114340. DOI: 10.1016/j.jep.2021.114340. [25] LI XJ, XU ZM, WANG SJ, et al. Emodin ameliorates hepatic steatosis through endoplasmic reticulum-stress sterol regulatory element-binding protein 1c pathway in liquid fructose-feeding rats[J]. Hepatol Res, 2016, 46( 3): E105- E117. DOI: 10.1111/hepr.12538. [26] HUANG C, ZHANG YQ, XU YJ, et al. Prepared radix polygoni multiflori and emodin alleviate lipid droplet accumulation in nonalcoholic fatty liver disease through MAPK signaling pathway inhibition[J]. Aging, 2024, 16( 3): 2362- 2384. DOI: 10.18632/aging.205485. [27] JINDAL A, JAGDISH RK, KUMAR A. Hepatic regeneration in cirrhosis[J]. J Clin Exp Hepatol, 2022, 12( 2): 603- 616. DOI: 10.1016/j.jceh.2021.08.029. [28] MANJUNATHAN R, VARGHESE D. A mechanistic overview on liver fibrogenesis[J]. Recent Res Endocrinol Metabol Dis, 2021, 3( 1): 7- 22. DOI: 10.2174/2666253103666210521162841. [29] PEARSON J, THOMSON E. Decompensated liver cirrhosis[J]. Anaesth Intensive Care Med, 2024, 25( 1): 42- 47. DOI: 10.1016/j.mpaic.2023.10.006. [30] HOANG DM, PHAM PT, BACH TQ, et al. Stem cell-based therapy for human diseases[J]. Signal Transduct Target Ther, 2022, 7( 1): 272. DOI: 10.1038/s41392-022-01134-4. [31] Viral Hepatitis Group of Professional Committee of Liver Disease(Combined Traditional Chinese and Western Medicine) of Chinese Research Hospital Association, Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases. Guidelines for fecal microbiota transplantation therapy in patients with liver cirrhosis[J]. J Clin Hepatol, 2025, 41( 3): 424- 431. DOI: 10.12449/JCH250306.中国研究型医院学会肝病(中西医结合)专业委员会病毒性肝炎学组, 浙江省慢性肝病重症化精准诊治与规模转化重点实验室. 肝硬化患者粪菌移植治疗指南[J]. 临床肝胆病杂志, 2025, 41( 3): 424- 431. DOI: 10.12449/JCH250306. [32] HE YF, WANG JC, WU FF, et al. Research progress of fecal bacteria transplantation in hepatobiliary and pancreatic surgery[J/OL]. Chin J Hepat Surg(Electronic Edition), 2025, 14( 4): 646- 653. DOI: 10.3877/cma.j.issn.2095-3232.2025.04.023.何勇飞, 王继才, 吴芬芳, 等. 粪菌移植在肝胆胰外科领域研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14( 4): 646- 653. DOI: 10.3877/cma.j.issn.2095-3232.2025.04.023. [33] GUO YR, SONG JW, LIU YS, et al. Study on the hepatotoxicity of emodin and its application in the treatment of liver fibrosis[J]. Molecules, 2024, 29( 21): 5122. DOI: 10.3390/molecules29215122. [34] MA QY, PAN GZ. Improvement effect of rhodopsin on the hepatic function and intestinal mucosal barrier damage in cirrhotic rats[J]. Int J Lab Med, 2025, 46( 8): 960- 964. DOI: 10.3969/j.issn.1673-4130.2025.08.012.马琦阳, 潘高展. 大黄素对肝硬化大鼠肝功能及肠黏膜屏障损伤的改善作用[J]. 国际检验医学杂志, 2025, 46( 8): 960- 964. DOI: 10.3969/j.issn.1673-4130.2025.08.012. [35] SAEIDINEJAD M, ELSHABRAWI A, SRIPHOOSANAPHAN S, et al. Novel therapeutic approaches in treatment of acute-on-chronic liver failure[J]. Semin Liver Dis, 2023, 43( 4): 429- 445. DOI: 10.1055/s-0043-1776773. [36] MAIWALL R, KULKARNI AV, ARAB JP, et al. Acute liver failure[J]. Lancet, 2024, 404( 10454): 789- 802. DOI: 10.1016/S0140-6736(24)00693-7. [37] YIN XR, GONG X, JIANG R, et al. Emodin ameliorated lipopolysacch‑aride-induced fulminant hepatic failure by blockade of TLR4/MD2 complex expression in D-galactosamine-sensitized mice[J]. Int Immunopharmacol, 2014, 23( 1): 66- 72. DOI: 10.1016/j.intimp.2014.08.018. [38] YIN RY, WEI FL, HU JH. Emodin improves L02 cell damage caused by D-GalN[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 5): 427- 429. DOI: 10.3969/j.issn.1005-0264.2023.005.011.尹瑞英, 魏飞力, 胡建华. 大黄素改善D氨基半乳糖胺造成的L02细胞损伤[J]. 中西医结合肝病杂志, 2023, 33( 5): 427- 429. DOI: 10.3969/j.issn.1005-0264.2023.005.011. [39] CAI YX, WANG WW, JIAO QL, et al. Nanotechnology for the diagnosis and treatment of liver cancer[J]. Int J Nanomedicine, 2024, 19: 13805- 13821. DOI: 10.2147/IJN.S490661. [40] ZHAO L, GUO ZQ, YANG Y, et al. Research advances in liver cancer organoids[J]. J Clin Hepatol, 2024, 40( 7): 1486- 1492. DOI: 10.12449/JCH240730.赵丽, 郭梓琪, 杨勇, 等. 肝癌类器官的研究进展[J]. 临床肝胆病杂志, 2024, 40( 7): 1486- 1492. DOI: 10.12449/JCH240730. [41] MARENGO A, ROSSO C, BUGIANESI E. Liver cancer: Connections with obesity, fatty liver, and cirrhosis[J]. Annu Rev Med, 2016, 67: 103- 117. DOI: 10.1146/annurev-med-090514-013832. [42] ANWANWAN D, SINGH SK, SINGH S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873( 1): 188314. DOI: 10.1016/j.bbcan.2019.188314. [43] SANGRO B, CHAN SL, KELLEY RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J]. Ann Oncol, 2024, 35( 5): 448- 457. DOI: 10.1016/j.annonc.2024.02.005. [44] HAO LY, LI SH, DENG JL, et al. The current status and future of PD-L1 in liver cancer[J]. Front Immunol, 2023, 14: 1323581. DOI: 10.3389/fimmu.2023.1323581. [45] ZHU Y, ZHAO Z, XU D, et al. Progress and prospect of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma[J/OL]. Chin J Hepat Surg(Electronic Edition), 2024, 13( 1): 5- 10. DOI: 10.3877/cma.j.issn.2095-3232.2024.01.002.朱迎, 赵征, 许达, 等. 免疫检查点抑制剂治疗肝细胞癌的进展与展望[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13( 1): 5- 10. DOI: 10.3877/cma.j.issn.2095-3232.2024.01.002. [46] HASSAN HM, HAMDAN AM, ALATTAR A, et al. Evaluating anticancer activity of emodin by enhancing antioxidant activities and affecting PKC/ADAMTS4 pathway in thioacetamide-induced hepatocellular carcinoma in rats[J]. Redox Rep, 2024, 29( 1): 2365590. DOI: 10.1080/13510002.2024.2365590. [47] QIN BY, ZENG ZL, XU JL, et al. Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and β-catenin[J]. BMC Cancer, 2022, 22( 1): 671. DOI: 10.1186/s12885-022-09684-0. [48] YAO Y, SHAO FQ, PENG XF, et al. Emodin in situ delivery with Pluronic F-127 hydrogel for myocardial infarction treatment: Enhancing efficacy and reducing hepatotoxicity[J]. Life Sci, 2024, 354: 122963. DOI: 10.1016/j.lfs.2024.122963. [49] XIE P, YAN LJ, ZHOU HL, et al. Emodin protects against lipopolysaccharide-induced acute lung injury via the JNK/Nur77/c-Jun signaling pathway[J]. Front Pharmacol, 2022, 13: 717271. DOI: 10.3389/fphar.2022.717271. [50] YANG F, DENG L, LI JP, et al. Emodin retarded renal fibrosis through regulating HGF and TGFβ-smad signaling pathway[J]. Drug Des Devel Ther, 2020, 14: 3567- 3575. DOI: 10.2147/DDDT.S245847. [51] ZENG P, WANG XM, YE CY, et al. Mechanistic insights into the anti-depressant effect of emodin: An integrated systems pharmacology study and experimental validation[J]. Aging, 2021, 13( 11): 15078- 15099. DOI: 10.18632/aging.203072. [52] XU YY, ZHU M, WU J, et al. A mannitol-modified emodin nano-drug restores the intestinal barrier function and alleviates inflammation in a mouse model of DSS-induced ulcerative colitis[J]. Chin Med, 2023, 18( 1): 98. DOI: 10.1186/s13020-023-00801-0. [53] NOWAK-PERLAK M, BROMKE MA, ZIÓŁKOWSKI P, et al. The comparison of the efficiency of emodin and Aloe-emodin in photodynamic therapy[J]. Int J Mol Sci, 2022, 23( 11): 6276. DOI: 10.3390/ijms23116276. -
下载:
本文二维码
图(1)
计量
- 文章访问数: 4
- HTML全文浏览量: 2
- PDF下载量: 2
- 被引次数: 0
